See more : Chicken Soup for the Soul Entertainment, Inc. (CSSEP) Income Statement Analysis – Financial Results
Complete financial analysis of NRx Pharmaceuticals, Inc. (NRXP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NRx Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PB Fintech Limited (POLICYBZR.BO) Income Statement Analysis – Financial Results
- Shandong Homey Aquatic Development Co.,Ltd. (600467.SS) Income Statement Analysis – Financial Results
- Koal Software Co., Ltd. (603232.SS) Income Statement Analysis – Financial Results
- Hyundai Steel Company (004020.KS) Income Statement Analysis – Financial Results
- Katakura Industries Co.,Ltd. (3001.T) Income Statement Analysis – Financial Results
NRx Pharmaceuticals, Inc. (NRXP)
About NRx Pharmaceuticals, Inc.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.00K | 4.00K | 2.00K | 907.41K | 0.00 | 1.01M | 0.00 |
| Gross Profit | -5.00K | -4.00K | -2.00K | -907.41K | 0.00 | -1.01M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.37M | 17.03M | 20.26M | 10.63M | 3.50K | 0.00 | 0.00 |
| General & Administrative | 14.22M | 27.37M | 74.94M | 11.44M | 2.77K | 0.00 | 0.00 |
| Selling & Marketing | -5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.21M | 27.37M | 74.94M | 11.44M | 2.77K | 1.01M | 0.00 |
| Other Expenses | 0.00 | -505.00K | -771.00K | -10.16M | 713.19K | 1.01M | 0.00 |
| Operating Expenses | 27.58M | 44.40M | 94.43M | 11.90M | 6.43K | 1.01M | 0.00 |
| Cost & Expenses | 27.59M | 44.40M | 94.43M | 11.90M | 6.43K | 1.01M | 0.00 |
| Interest Income | 494.00K | 249.00K | 18.00 | 56.00 | 1.21M | 1.09M | 0.00 |
| Interest Expense | 120.00K | 0.00 | 18.00K | 56.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.00K | 4.00K | 2.00K | 2.00K | 0.86 | 1.09M | 52.52K |
| EBITDA | -30.03M | -39.75M | -93.04M | -51.72M | -713.19K | 82.41K | -105.04K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -27.59M | -44.40M | -115.80M | -51.39M | -6.26K | -1.01M | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.57M | 4.58M | 22.73M | -39.88M | 1.21M | 1.09M | -105.03K |
| Income Before Tax | -30.16M | -39.82M | -93.06M | -51.78M | 492.63K | 82.41K | -105.03K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -9.00K | -4.58M | -21.35M | -39.43M | 84.21K | 16.31K | 0.00 |
| Net Income | -30.15M | -35.24M | -71.72M | -12.35M | 408.43K | 66.10K | -105.03K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.98 | -0.54 | -1.53 | -0.36 | 0.80 | 0.07 | -0.12 |
| EPS Diluted | -3.98 | -0.54 | -1.53 | -0.36 | 0.80 | 0.07 | -0.12 |
| Weighted Avg Shares Out | 7.58M | 65.77M | 46.92M | 34.27M | 508.84K | 892.50K | 903.55K |
| Weighted Avg Shares Out (Dil) | 7.58M | 65.77M | 46.92M | 34.27M | 508.84K | 892.50K | 903.55K |
NRx Pharmaceuticals (NRXP) Upgraded to Buy: Here's Why
NRx Pharmaceuticals (NRXP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024
WILMINGTON, Del., Nov. 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman, CEO and Chief Scientist will present at NobleCon20 - Noble Capital Markets' Twentieth Annual...
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials"
NRx-developed training and monitoring methodology in recently completed phase 2b/3 clinical trial of NRX-101 documents higher interrater reliability (IRR) on primary endpoint (MADRS depression scale) than previously reported industry standards Positive implications for conduct of future registration trials for NRX-101...
NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q3 2024 Earnings Conference Call November 18, 2024 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Jonathan Javitt - Founder, Chairman and Chief Scientist Richard Narido - Interim Chief Financial Officer and...
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer
Industry veteran with extensive experience in key areas of focus Interim-CFO Richard Narido to focus on HOPE Therapeutics acquisition opportunities WILMINGTON, Del., Nov. 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today...
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update
On track to file New Drug Applications (NDAs) for NRX-100 (IV Ketamine) in treating suicidal ideation in depression, including bipolar depression and NRX-101 (Oral D-Cycloserine/Lurasidone) for Accelerated Approval in bipolar depression with suicidality or akathisia by year end 2024 with...
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024
WILMINGTON, Del. , Nov. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will reschedule its third quarter and year to date 2024 results conference call to Monday...
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024
WILMINGTON, Del. , Nov. 7, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter and year to date 2024 financial results after the market...
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics
The clinics are located in favorable locations, are revenue generating and EBITDA positive Clinics offer a comprehensive range of mental health services Acquisition is expected to be immediately accretive to revenue and EBITDA for HOPE and NRx MIAMI , Oct....
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024
MIAMI, FL., October 23, 2024 – PRISM MediaWire – NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc.
Source: https://incomestatements.info
Category: Stock Reports